Active immunization against cancer with dendritic cells: The near future

International Journal of Cancer

Volumn 94, Issue 4, 2001, Pages 459-473

  Steinman, Ralph M ^a   Dhodapkar, Madhav ^a,b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 IMMUNOGLOBULIN; CD8 ANTIGEN; INTERLEUKIN 10; VIRUS VECTOR;

ACTIVE IMMUNIZATION; ANTIGEN PRESENTING CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELL MATURATION; CELL MIGRATION; CELL MOTILITY; CELL POLARITY; DENDRITIC CELL; DOSE RESPONSE; HUMAN; IMMUNOSTIMULATION; KIDNEY CARCINOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CARCINOMA; SHORT SURVEY; SUBCUTANEOUS DRUG ADMINISTRATION; TH1 CELL; TREATMENT OUTCOME;

CANCER VACCINES; CLINICAL TRIALS; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; MODELS, BIOLOGICAL; NEOPLASMS; PHENOTYPE; PLASMIDS; T-LYMPHOCYTES; TREATMENT OUTCOME; VACCINATION;

EID: 0035889647     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1503     Document Type: Short Survey

References (294)

1. Immunobiology of dendritic cells
2. Dendritic cell regulation of Th1-Th2 development
3. The dendritic cell and human cancer vaccines
4. The cell biology of antigen presentation in dendritic cells
5. Dendritic cells as the "conductors" of the immune response
6. Resting respiratory tract dendritic cells preferentially stimulate T helper cell type 2 (Th2) responses and require obligatory cytokine signals for induction of Th1 immunity
7. Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli
8. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage
9. The formation of immunogenic MHC class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli
10. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells
11. Developmental regulation of MHC class II transport in mouse dendritic cells
12. Transport of peptide-MHC class II complexes in developing dendritic cells
13. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells
14. + hematopoietic progenitors induces their proliferation and differentiation into functional dendritic cells
15. - T lymphocytes by 4-1BB ligand
16. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell specific survival factor
17. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation
18. CD47 engagement inhibits cytokine production maturation of human dendritic cells
19. Regulatory activity of autocrine IL-10 on dendritic cell functions
20. Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer
21. + T cell adoptive immunotherapy
22. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow
23. In vivo microbial stimulation induces rapid CD40L-independent production of IL-12 by dendritic cells their re-distribution to T cell areas
24. The nature of the principal type 1 interferon-producing cells in human blood
25. + lymphoid dendritic cells
26. Tumor cell responses to IFN-γ affect tumorigenicity response to IL-12 therapy and anti-angiogenesis
27. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN-γ receptor expression by nonhematopoietic cells
28. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ
29. IFN-γ lymphocytes prevent primary tumour development and shape tumour immunogenicity
30. Demonstration of an interferon-γ- dependent tumor surveillance system in immunocompetent mice
31. Active immunization against cancer cells: Impediments and advances
32. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance
33. The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells
34. Tumor immunology: The glass is half full
35. A new era for cancer immunotherapy based on the genes that encode cancer antigens
36. The makings of a tumor rejection antigen
37. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo
38. + T cells with regulatory properties by repetitive stimulation with allogeneic immature dendritic cells
39. Antigen specific inhibition of effector T cell function in humans after injection of immature dendritic cells
40. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
41. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
42. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
43. + melanoma patients by mature monocyte-derived dendritic cells
44. Rapid generation of broad T-cell immunity in humans after single injection of mature dendritic cells
45. Immunologic therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
46. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical, vulvar intraepithelial neoplasia who are HPV 16 positive
47. + T cell responses in antitumor immunity
48. CD4 T cells and their role in antitumor immune responses
49. + T helper and a T-killer cell
50. Help for cytotoxic-T-cell responses is mediated by CD40 signalling
51. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
52. + T cell subsets during virus infection: Protective capacity depends on effector cytokine secretion and on migratory capability
53. Distinct roles of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo
54. Migration kinetics and final destination of type 1 and type 2 CD8 effector cells predict protection against pulmonary virus infection
55. + T cells
56. CD4(+) T cell-mediated control of a γ-herpesvirus in B cell-deficient mice is mediated by IFN-γ
57. P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflamed tissues
58. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes
59. Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential
60. Mechanism and biological significance of CD4-mediated cytotoxicity
61. Helper activity for immunoglobulin synthesis of T helper type 1 (Th1) and Th2 human T cell clones: The help of Th1 clones is limited by their cytolytic capacity
62. Protective antiviral cytotoxic T cell memory is most efficiently maintained by restimulation via dendritic cells
63. TRANCE, a tumor necrosis family member, enhances the longevity and adjuvant properties of dendritic cells in vivo
64. Cellular interactions involved in Th cell memory
65. TRANCE, a TNF-family member is differentially expressed on T cell subsets and induces cytokine production in dendritic cells
66. Induction of IL-15 messenger RNA and protein in human blood-derived dendritic cells
67. Dendritic cell secretion of IL-15 is induced by recombinant huCD40L and augments the stimulation of antigen-specific cytolytic T cells
68. + memory T cells by opposing cytokines
69. Mature dendritic cells boost functionally superior T cells in humans without foreign helper epitopes
70. T cell affinity maturation by selective expansion during infection
71. A kinetic basis for T-cell receptor repertoire selection during an immune response
72. Role of antigen, CD8 and cytotoxic T lymphocyte [CTL] avidity in high dose antigen induction of apoptosis of effector CTL
73. High avidity CTLs for 2 self-antigens demonstrate superior in vitro and in vivo antitumor efficacy
74. Differentiation of T regulatory cells by immature dendritic cells
75. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex
76. Localization, quantitation and in situ detection of specific peptide - MHC class I complexes using a monoclonal antibody
77. A comparison of two types of dendritic cells as adjuvants for the induction of melanoma-specific T cell responses in humans following intranodal injection
78. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12
79. Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells
80. Production of interleukin-12 by human monocyte-derived dendritic cells is optimal when the stimulus is given at the onset of maturation and is further enhanced by interleukin-4
81. - dendritic cells
82. Final maturation of dendritic cells is associated with impaired responsiveness to IFN-γ and to bacterial IL-12 inducers: Decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells
83. Kinetics of dendritic cell activation: Impact on priming of Th1 and Th2 and nonpolarized T cells
84. + IFN-γ-producing T cells from tumor-infiltrating lymphocytes
85. The expanding B7 superfamily: Increasing complexity in costimulatory signals regulating T cell function
86. The tissue distribution of the B7-2 costimulator in mice: Abundant expression on dendritic cells in situ and during maturation in vitro
87. ICOS is essential for effective T-helper-cell responses
88. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells
89. B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
90. Generation of mature dendritic cells from human blood: An improved method with special regard to clinical applicability
91. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ
92. + T cells
93. CD40-CD40 ligand interactions in vivo regulate migration of antigen-bearing dendritic cells from the skin to draining lymph nodes
94. Migration of human dendritic cells after injection in patients with metastatic malignancies
95. A physiologic function for P-glycoprotein (MDR-1) during the mobilization of dendritic cells
96. The leukotriene C4 transporter MRP1 regulates CCL19 (MIP-3βELC)-dependent mobilization of dendritic cells to lymph nodes
97. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs
98. Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs
99. Human monocyte-derived dendritic cells induce naive T cell differentiation into T helper cell type 2 (Th2) or Th1/Th2 effectors. Role of stimulator/responder ratio
100. + T helper cell phenotype development in a T-cell receptor-α β-transgenic model
101. + T cells
102. + T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity
103. Biodistribution vaccine efficiency of murine dendritic cells are dependent on the route of administration
104. T cell activity after dendritic cell vaccination is dependent on both the type of antigen and the mode of delivery
105. Dendritic cells injected via different routes induce immunity in cancer patients
106. Local administration of dendritic cells inhibits established breast cancer growth: Implications for apoptosis inducing agents
107. A subset of cytolytic dendritic cells in rat
108. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
109. In vitro growth inhibition of a broad spectrum of tumor cell lines by activated human dendritic cells
110. Generation of large numbers of fully mature stable dendritic cells from leukapheresis products for clinical application
111. A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use
112. Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium
113. Human blood contains 2 subsets of dendritic cells, one immunologically mature and the other immature
114. Replicative response, immunophenotype and functional activity of monocyte-derived versus CD34(+)-derived dendritic cells following exposure to various expansion and maturational stimuli
115. + progenitor-derived dendritic cells in patients with stage IV melanoma
116. + hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+ TNF-α
117. + hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor α. II. Functional analyses
118. + progenitors
119. Dendritic cells enhance growth differentiation of CD40-activated B lymphocytes
120. 27-35-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors
121. + T cells
122. Transforming growth factor β1, in the presence of granulocyte/macrophage colony-stimulating factor and interleukin 4, induces differentiation of human peripheral blood monocytes into dendritic Langerhans cells
123. Immature dendritic cells generated from monocytes in the presence of TGF-β1 express functional C-C chemokine receptor 6
124. The enigmatic plasmacytoid T cells develop into dendritic cells with IL-3 and CD40-ligand
125. Plasmacytoid monocytes migrate to inflamed lymph nodes produce large amounts of type I interferon
126. Differentiation of monocytes into dendritic cells in a model that mimics entry of cells into afferent lymph
127. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo
128. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens
129. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice
130. Reciprocal control of T helper cell and dendritic cell differentiation
131. Natural interferon-α/β-producing cells link innate and adaptive immunity
132. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo
133. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells
134. Generation of interferon-α-producing predendritic cell (pre-DC)2 from human CD34(+) hematopoietic stem cells
135. Id2 and Id3 inhibit development of CD34(+) stem cells into predendritic cell (pre-DC)2 but not into pre-DC1. Evidence for a lymphoid origin of pre-DC2
136. Efficient presentation of phagocytosed cellular fragments on the MHC class II products of dendritic cells
137. RNA-transfected dendritic cells in cancer immunotherapy
138. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells
139. Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes
140. DNA vaccines: Immunology, application and optimization
141. Antigen presentation by dendritic cells following immunization with DNA encoding a class II-restricted viral epitope
142. Dendritic cells at a DNA vaccination site express the encoded influenza nucleoprotein and prime MHC class I-restricted cytolytic lymphocytes upon adoptive transfer
143. Predominant role for directly transfected dendritic cells in antigen presentation to CD8(+) T cells after gene gun immunization
144. DNA vaccination: Transfection and activation of dendritic cells as key events for immunity
145. Efficient nonviral transfection of dendritic cells their use for in vivo immunization
146. Cancer vaccines
147. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides
148. Vaccines against intracellular infections requiring cellular immunity
149. Viral vectors for dendritic cell-based immunotherapy
150. Recombinant adenovirus is an efficient non-perturbing genetic vector for human dendritic cells
151. Presentation of SIVgag to monkey T cells using dendritic cells transfected with a recombinant adenovirus
152. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model tumor antigen induce protective therapeutic antitumor immunity
153. DNA vaccines
154. Induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or UV-inactivated, recombinant EBNA-3A vaccinia virus
155. Vaccinia virus inhibits the maturation of human dendritic cells a novel mechanism of immune evasion
156. + T cell responses from chronically infected individuals
157. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1
158. Canarypox-induced maturation of dendritic cells is mediated by apoptotic cell death and tumor necrosis factor-α secretion
159. Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1)
160. Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes
161. +T cells from HIV-1 infected individuals
162. Efficient expression of the tumor-associated antigen MAGE-3 in human dendritic cells, using an avian influenza virus vector
163. DC-SIGN, a dendritic cell specific HIV-1 binding protein that enhances TRANS-infection of T cells
164. Immunosuppression resultant viral persistence by specific viral targeting of dendritic cells
165. Human skin Langerhans cells are targets of dengue virus infection
166. The role of aquaporins in dendritic cell macropinocytosis
167. Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms and sensitize mice to mycobacterial antigens in vivo
168. s and CD36 and cross-present antigens to cytotoxic T lymphocytes
169. Corpse clearance defines the meaning of cell death
170. Dendritic cells use macropinocytosis and the mannose receptor to concentrate antigen in the major histocompatibility class II compartment. Downregulation by cytokines and bacterial products
171. Developmental control of endocytosis in dendritic cells by Cdc42
172. 4, lysosomal compartments
173. Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization
174. The B subunit of shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens
175. Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes
176. Presentation of proteins encapsulated into sterically stabilized liposomes by dendritic cells initiates CD8(+) T cell responses in vivo
177. Influences of transporter associated with antigen processing (TAP) on the repertoire of peptides associated with the endoplasmic reticulum-resident stress protein gp96
178. Induction of vigorous helper cytotoxic T cell as well as B cell responses by dendritic cells expressing a modified antigen targeting receptor-mediated internalization pathway
179. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide
180. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity
181. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96
182. Cross-presentation of glyco-protein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis
183. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via 2 distinct processing pathways
184. CD91: A receptor for heat shock protein gp96
185. Heat shock protein gp96 induces maturation and migration of CD11c(+) cells in vivo
186. The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor
187. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
188. + T cells for efficient tumor cell lysis
189. Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8(+) killer T cells
190. Tumor-specific and anti-neuronal killer cells in paraneoplastic cerebellar degeneration
191. Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response
192. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells
193. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses
194. Consequences of cell death. Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
195. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κB pathway
196. Role of dendritic cells in the induction maintenance of autoimmune diseases
197. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease
198. The induction of tolerance by dendritic cells that have captured apoptotic cells
199. Dendritic cells up-regulate immunoproteasomes and the proteasome regulator PA28 during maturation
200. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells
201. Structural requirements for high affinity binding of complex ligands by the macrophage mannose receptor
202. The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD bos helicase p68
203. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma
204. A p16 INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
205. Induction of antitumor activity by immunization with fusions of dendritic carcinoma cells
206. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity
207. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
208. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming
209. Dendritic cells or their exosomes are effective biotherapies of cancer
210. Interleukin-1 polymorphisms associated with increased risk of gastric cancer
211. Autologous dendritic cells for treatment of advanced cancer - An update
212. New paths in human cancer serology
213. Human tumor antigens recognized by T lymphocytes
214. Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses
215. + hematopoietic progenitor cells
216. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100
217. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen
218. Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment
219. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease
220. Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients
221. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides
222. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
223. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer
224. Dendritic cell-based immunotherapy of prostate cancer: Immune monitoring of a phase II clinical trial
225. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: A feasibility study
226. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma
227. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma
228. Dendritic cell vaccines for cancer immunotherapy
229. Papillomavirus infections - A major cause of human cancers
230. Cervical cancer vaccines: Emerging concepts and developments
231. Accessing Epstein-Barr virus-specific T-cell memory with peptide-loaded dendritic cells
232. + T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function
233. Replication of HIV-1 in dendritic cell-derived syncytia at the mucosal surface of the adenoid
234. Localization of distinct Peyer's patch dendritic cell subsets and their recruitment by chemokines macrophage inflammatory protein (MIP)-3α MIP-3β secondary lymphoid organ chemokine
235. Macrophage inflammatory protein 3α is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors
236. CCR6 mediates dendritic cell localization, lymphocyte homeostasis and immune responses in mucosal tissue
237. Dendritic cell-based immunotherapy of renal cell carcinoma
238. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells
239. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
240. Treatment of solid turnouts in children with tumour-lysate-pulsed dendritic cells
241. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration
242. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
243. Present difficulties and future promise of MHC multimers in autoimmune exploration
244. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers
245. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers
246. + T cells in chronically infected HIV-1 positive individuals
247. +, interferon-γ-secreting, T lymphocytes
248. Paucity of function T-cell memory to melanoma antigens in healthy donors and melanoma patients
249. Assessing CD8 T cell number and dysfunction in the presence of antigen
250. Advances in vaccine adjuvants
251. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation activation of murine dendritic cells
252. Enhanced dendritic cell maturation by TNF-α or CpG DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo
253. CpG DNA: A potent signal for growth, activation and maturation of human dendritic cells
254. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization
255. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: A role for dendritic cells in the augmentation of TH1 responses by immunostimulatory DNA
256. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice
257. + T cells
258. + T cell tolerance to peripherally expressed antigens
259. Peripheral tolerance of CD4 T cells following local activation in adolescent mice
260. + T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells
261. Cross-presentation of tumor antigens by bone marrow derived antigen presenting cells is the dominant mechanism in the induction of T cell tolerance during B-cell lymphoma progression
262. + progenitors by tumor cells: Role of interleukin-6 and macrophage colony-stimulating factor
263. Follow the leader: NK cell receptors for classical and nonclassical MHC class I
264. Activating receptors coreceptors involved in human natural killer cell-mediated cytolysis
265. Recognition of autologous dendritic cells by human NK cells
266. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells
267. 2B4 functions as a co-receptor in human NK cell activation
268. Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo
269. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas
270. The interface between innate and acquired immunity: Glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes
271. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides
272. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells in IL-12-mediated rejection of tumors
273. Inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide
274. Murine CD1d-restricted T cell recognition of cellular lipids
275. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NK-T cells
276. Antitumor cytotoxicity mediated by ligand-activated human Vα24 NKT cells
277. FBL-reactive CD8 cytotoxic and CD4 helper T cells recognize distinct friend murine leukemia virus-encoded antigens
278. + T cells in the antitumor immune response
279. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors
280. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells
281. CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes
282. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation
283. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients
284. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses
285. APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells
286. Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: Implications for the augmentation of Th1 responses
287. + T cell help to elicit antitumor immunity: Implications for the clinical use of dendritic cells
288. Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins
289. In search of the "missing self": MHC molecules and NK cell recognition
290. Mature dendritic cells respond to SDF-1, but not to several β chemokines
291. EB11/CCR7 is a new member of dendritic cell chemokine receptor that is upregulated upon maturation
292. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily
293. A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartment